Vistagen Therapeutics (VTGN) Assets Average (2017 - 2025)
Vistagen Therapeutics (VTGN) has disclosed Assets Average for 11 consecutive years, with $73.0 million as the latest value for Q4 2025.
- Quarterly Assets Average fell 25.06% to $73.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $73.0 million through Dec 2025, down 25.06% year-over-year, with the annual reading at $104.0 million for FY2025, 43.7% up from the prior year.
- Assets Average hit $73.0 million in Q4 2025 for Vistagen Therapeutics, down from $74.9 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $127.4 million in Q1 2024 to a low of $18.1 million in Q2 2023.
- Historically, Assets Average has averaged $78.5 million across 5 years, with a median of $84.6 million in 2022.
- Biggest five-year swings in Assets Average: skyrocketed 1859.38% in 2021 and later crashed 72.92% in 2023.
- Year by year, Assets Average stood at $95.5 million in 2021, then plummeted by 63.14% to $35.2 million in 2022, then skyrocketed by 146.08% to $86.6 million in 2023, then increased by 12.43% to $97.4 million in 2024, then fell by 25.06% to $73.0 million in 2025.
- Business Quant data shows Assets Average for VTGN at $73.0 million in Q4 2025, $74.9 million in Q3 2025, and $76.6 million in Q2 2025.